Abstract library

33 results for "Teulé Vega".
#154 Long-term disease stabilization in a patient with advanced pancreatic neuroendocrine tumor treated with combined everolimus and octreotide LAR after prior failure of cytotoxic therapy
Introduction: Targeting of multiple pathways has become an important strategy for improved tumor control in metastatic neuroendocrine tumors (NETs). Among these targets is the mammalian target of rapamycin (mTOR), a central regulator of cell growth, proliferation, and apoptosis, which is blocked by everolimus, an oral inhibitor of mTOR that has shown efficacy in patients with metastatic pancreatic NETs. Recent evidence has suggested that suppression of insulin-like growth factor-1 receptor (IGF-1R) secretion with octreotide therapy, along with concurrent inhibition of mTOR by everolimus, may improve tumor control synergistically by preventing feedback activation of the PI3K/Akt/mTOR pathway.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Alexandre Teulé Vega
#491 International Survey for the Use of Biomarkers and Molecular Imaging in Neuroendocrine Tumors (NET): What we are Using in Daily Practice
Introduction: Several guidelines have given recommendations for optimal use of biomarkers and molecular imaging. However, those guidelines’ implementation may not be always possible due to local policies or lack of access to several diagnostic studies.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: DR CHRISTOS Toumpanakis
#1326 Clinical Nurse Specialist in NET Patients at Institut Català d’ Oncologia - ICO
Introduction: A Functional Unit model brings together multidisciplinary professionals participating in a committee. Its aim is to optimize diagnostic and therapeutic intervals, get consensus on the best-individual treatment option & best evidence. Our unit-NET, was establish 10 years ago & last 4 got a clinical nurse specialist-CNS
Conference: 13th Annual ENETS conference (2016)
Category: ...none of the above
Presenting Author: RN, PhDcandidate Paz Fernandez
Keywords: Clinical nurse
#1526 Therapeutic Strategies in Patients with Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NEN): Results from the National Neuroendocrine Cancer Registry of Spain (R-GETNE)
Introduction: The Spanish National Neuroendocrine Cancer Registry is a hospital-based registry of GEP-NENs launched by GETNE in 2001.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Others
Presenting Author: PhD Paula Jimenez-Fonseca
#1532 Epidemiology, Pathological Features and Clinical Outcome of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs): Results from the National Neuroendocrine Cancer Registry of Spain (R-GETNE)
Introduction: The Spanish National Neuroendocrine Cancer Registry is a hospital-based registry of GEP-NENs coordinated by the scientific multidisciplinary Spanish society GETNE, that covers 57 academic and community sites representing all regions of Spain.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: PhD Paula Jimenez-Fonseca
#1563 Impact of Early Surgery on Prognosis in Advanced Gastro-entero-pancreatic Neuroendocrine Tumours (GEP-NET)
Introduction: In gastro-entero-pancreatic neuroendocrine tumours (GEP-NET) the role of surgery remains to be determined.
Conference: 13th Annual ENETS conference (2016)
Category: Surgical treatment
Presenting Author: MD Patrizia Kump
#1587 LRIG1 Was Down-Regulated in Medullary Thyroid Cancer but No Significant Effect of LRIG1 Was Found in RET2B Transgenic Mice and Human Differentiated Thyroid Cancer
Introduction: There are four main types of thyroid cancer, papillary (PTC), follicular (FTC), medullary (MTC), and anaplastic. In both PTC and MTC, genomic rearrangements and point mutations in the proto-oncogene RET are common. RET encodes a receptor tyrosine kinase that is negatively regulated by leucine-rich repeats and immunoglobulin-like domains-1 (LRIG1). LRIG1 gene status and mRNA and protein expression correlate with patient survival in different types of cancer.
Conference: 14th Annual ENETS conference (2017)
Category: Biomarkers
Presenting Author: Associate profes David Lindquist
Keywords: LRIG1, RET, MTC
#1710 Observational Study of Small Pancreatic Neuroendocrine Incidentalomas: A Tertiary Referral Center Experience
Introduction: Incidence in small pancreatic neuroendocrine incidentalomas (PNETs-I) are increasing and its management remains controversial
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Inmaculada Peiró Martínez
Keywords: PNETs
#1734 Efficacy of Lanreotide (LAN), Both Alone and in Combination with Targeted Therapies in a Preclinical Model of Pancreatic Neuroendocrine Tumors (pNETs)
Introduction: CLARINET trial has proven the antiproliferative effects of LAN in patients with non-functioning gastro-entero-pNETs. However, the combination of LAN with targeted therapies is widely used in clinical practice and should be further evaluated.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: PhD Oriol Casanovas
Keywords: Lanreotide, pNET
#1757 Therapeutic Strategies in Patients with Neuroendocrine Neoplasm: 30 Month Follow-Up pf Long Survivors from EPH Mostaganem and EHU Oran Medical Oncology
Introduction: Neuro docrine tumors are poorly known and infrequent tumors are, most of the time, diagnosed late, often occurring between the age of 40 and 60.They mainly appear in the gastro intestinal system, pancreas, bronchi, lungs, thymus and thyroid.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Aicha Bengueddach